TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Oscar Health Inc (OSCR)

Healthcare Healthcare Plans
31.20 $
+0.0% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Oscar Health Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 31 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Trading Day

Previous Close
31.20$
Open
31.10$
Day High
31.70$
Day Low
30.20$
Volume
3,441,542shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
10.90 $ 32.20 $
03/30/2026 07/02/2026

Current price 31.20 $ — 95% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
9.0$B
Shares Outstanding
266Mio.
Float
93.7%
Beta
2.3

Performance

Perf. 1M
31.90%
Perf. 3M
164.40%
Perf. 6M
97.30%
YTD Performance (%)
108.30%
52-Week-High Distance
-5.6%
Perf. 1Y
122.21%
Perf. 3Y
315.16%
Perf. 5Y
84.41%
Perf. Since Inception
-10.29%

Technical Indicators

MA 38 Days
29.70$
MA 50 Days
28.00$
MA 200 Days
18.90$
RSI (14)
57.7
Volatility 30 Days
59.8%
Volatility 250 Days
70.0%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
588.2
PEG
P/B
5.7
P/S
0.7
EV/EBITDA
0.0
Price/FCF
3.2

Profitability

Gross Margin
17.4%
EBIT Margin
15.2%
Net Margin
-0.3%
Return on Equity
-2.6%
Return on Assets
0.1%

Balance Sheet & Safety

Equity Ratio
17.9%
Debt/Equity
0.3
Altman Z″
3.00
Piotroski
7 out of 9

Growth

Sales Growth Last Quarter
52.60%
EPS Growth Last Quarter
125.60%
Sales Growth (Year)
27.50%
Forward Sales Growth
6.84%
Forward EPS Growth
36.20%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
Top 10%
RS Rating
94
EPS Rating
87
Piotroski
7 out of 9
Fundamental Rating
B (64 out of 100)
Altman Z″
3.00

AI Rating

Uses AI

Oscar Health nutzt KI operativ und breit im eigenen Technologie-Stack: Laut Geschäftsbericht (10-K) für 2025 sind KI-Technologien in Automatisierung (virtuelle Versorgung, Abrechnungsverarbeitung), Mitglieder-Personalisierung und digitale Self-Service-Funktionen eingebettet; 2025 startete zudem der persönliche KI-Agent „Oswell“ für Mitglieder. Eine KI-Umsatzquelle ist nicht dokumentiert (die +Oscar-Plattformerlöse sind unwesentlich), und die Risikofaktoren behandeln nur Risiken aus der eigenen KI-Nutzung — daher „Nutzt KI“.

View the full file — quotes, sources, reviewed filings
„We have embedded AI Technologies across many aspects of our technology stack, including: (i) automation to drive efficiencies in our administrative functions, including virtual care and claims processing, (ii) member personalization, to improve the quality of touchpoints members have with the healthcare ecosystem; and (iii) digital self-service and member-facing agent capabilities to facilitate care and improve the member experience."

Wir haben KI-Technologien in viele Bereiche unseres Technologie-Stacks eingebettet, darunter: (i) Automatisierung, um Effizienzgewinne in unseren Verwaltungsfunktionen zu erzielen, einschließlich virtueller Versorgung und Abrechnungsverarbeitung, (ii) Mitglieder-Personalisierung, um die Qualität der Berührungspunkte der Mitglieder mit dem Gesundheitssystem zu verbessern, und (iii) digitale Self-Service- und mitgliederorientierte Agenten-Funktionen, um die Versorgung zu erleichtern und das Mitgliedererlebnis zu verbessern.

10-K · 2026-02-13 · View SEC filing
„Our business currently utilizes AI Technologies to drive efficiencies in our business, including by deploying use cases that are designed to streamline administrative processes, improve the experience for our members and providers and enhance our decision making capabilities. We are making, and plan to make in the future, investments in adopting AI Technologies across our business and across our technology stack. For example, in 2025, we launched Oswell, a personal AI agent designed to provide our members with on-demand support and doctors with data to improve care paths."

Unser Geschäft nutzt KI-Technologien derzeit, um Effizienzgewinne zu erzielen — unter anderem mit Anwendungsfällen, die Verwaltungsprozesse verschlanken, das Erlebnis für unsere Mitglieder und Leistungserbringer verbessern und unsere Entscheidungsfähigkeit stärken sollen. Wir investieren — und planen auch künftig zu investieren — in die Einführung von KI-Technologien in unserem gesamten Geschäft und Technologie-Stack. So haben wir 2025 Oswell gestartet, einen persönlichen KI-Agenten, der unseren Mitgliedern Unterstützung auf Abruf bietet und Ärzten Daten zur Verbesserung der Behandlungspfade liefert.

10-K · 2026-02-13 · View SEC filing
„Leveraging AI enabled member and provider service touch points to provide high quality, impactful services at scale, including chatbots to answer health, wellness and insurance plan questions."

Nutzung KI-gestützter Service-Kontaktpunkte für Mitglieder und Leistungserbringer, um hochwertige, wirkungsvolle Dienste in großem Maßstab zu erbringen — einschließlich Chatbots, die Fragen zu Gesundheit, Wohlbefinden und Versicherungsplänen beantworten.

10-K · 2026-02-13 · View SEC filing

Filings Reviewed: 10-Q 2026-05-07 · 10-Q 2025-11-06 · 10-Q 2025-08-07 · 10-Q 2025-05-08 · 10-K 2026-02-13 · 10-K 2025-02-20

Rated on July 9, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 31.20 $
Price Target (average) 25.20 $

The price target sits 19.2% below the current price.

Consensus
Hold
Analyst Ratings
7
Distribution of Recommendations
Strong Buy 2
Buy 1
Hold 2
Sell 1
Strong Sell 1

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 1.11 0.75 – 1.49 18,573 165.7% 10
12/31/2027 1.57 1.00 – 2.25 19,779 41.0% 10

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

6. Aug 2026 · before the open · Q2 2026
Expected Earnings per Share
0.43 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 2,392.4 $M Q4 2025: Q1 · 3,046.3 $M Q1 2025: Q2 · 2,863.9 $M Q2 2025: Q3 · 2,986.0 $M Q3 2025: Q4 · 2,805.2 $M Q4 2026: Q1 · 4,647.2 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.58 2,392 67.10 -6.40 347 340
2025: Q1 0.90 49.00 3,046 42.20 9.00 879 870
2025: Q2 -0.85 -557.00 2,864 29.00 -8.00 509 500
2025: Q3 -0.53 2,986 23.20 -4.60 -965 -974
2025: Q4 -1.24 2,805 17.30 -12.60 672 663
2026: Q1 2.06 128.90 4,647 52.60 14.60 2,619 2,610
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2019 554 -259 -261 -9.06 -165 853 1,347
2020 590 -406 -407 -13.90 223 -1,296 2,272
2021 1,921 -571 -573 -3.20 -182 1,387 3,322
2022 4,126 -610 -606 -2.85 380 890 4,527
2023 5,863 -236 -271 -1.22 -272 804 3,601
2024 9,178 57 25 0.10 978 1,014 4,841
2025 11,701 -396 -443 -1.69 1,095 978 6,325

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Oscar Health, Inc. ist als Gesundheitstechnologieunternehmen in den USA tätig.

Employees2,305
HeadquartersNew York, NY
Address75 Varick Street, 10013 New York, United States
Phone646 403 3677
Websitehioscar.com
IPO Date3. Mar 2021
ISINUS6877931096

Management

Management
Name Title Birth Year
Mark Thomas Bertolini CEO & Director 1957
Joshua Kushner Co-Founder & Vice Chairman 1985
Mario Tobias Schlosser Co-Founder, Advisor to the CEO & Director 1979
Richard Scott Blackley CPA Chief Financial Officer 1968
Adam McAnaney EVP & Chief Legal Officer 1977
Janet Ann Liang EVP & President of Oscar Insurance 1968
Victoria Baltrus Chief Accounting Officer 1970
Chris Potochar Vice President of Treasury & Investor Relations
Rebecca Krouse Chief People Officer
Joel I. Klein J.D. Senior Advisor 1947

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?